Neurexis Therapeutics is developing tatCN19o, an FDA-approved neuroprotective peptide designed for intravenous administration within four hours of ischemic events such as stroke and cardiac arrest. This therapy aims to significantly reduce neuronal death and cognitive impairment, addressing the substantial healthcare costs and quality of life issues associated with these conditions.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Ischemic events like stroke and cardiac arrest lead to neuronal death and cognitive impairment, resulting in substantial healthcare costs and reduced quality of life for millions. Re-establishment of blood flow, while life-saving, paradoxically triggers proinflammatory events that exacerbate nerve cell damage. Currently, there are no FDA-approved drugs available to directly address this neuronal damage.
Solution
Neurexis Therapeutics is developing tatCN19o, a neuroprotective peptide administered intravenously within four hours of an ischemic event. This therapy aims to mitigate neuronal death and subsequent cognitive impairment by intervening in the cascade of proinflammatory events triggered by the restoration of blood flow. By reducing brain damage, tatCN19o seeks to improve patient outcomes, lessen long-term disability, and alleviate the burden on healthcare systems. The peptide has demonstrated efficacy and safety in preclinical studies using both small and large animal models of global cerebral ischemia.
Target Audience
The primary target audience includes patients at risk of or experiencing ischemic events such as stroke and cardiac arrest, as well as healthcare providers and hospitals treating these conditions.
Features
- Intravenous administration within a four-hour window following an ischemic event.
- Neuroprotective mechanism targeting the reduction of neuronal death.
- Designed to mitigate cognitive impairment resulting from ischemic injury.
- Demonstrated efficacy and safety in preclinical animal models of global cerebral ischemia.